Hologic (HOLX) late Wednesday reported fiscal Q1 non-GAAP earnings of $1.03 per diluted share, up from $0.98 a year earlier.
Analysts polled by FactSet, on average, expected $1.02.
Net sales for the quarter ended Dec. 28 were $1.02 billion compared with $1.01 billion a year earlier. Analysts expected $1.02 billion.
For Q2, the health care company is looking for non-GAAP EPS of $1.00 to $1.03 on revenue of $995 million to $1.01 billion. Analysts are expecting $1.04 and $1.03 billion, respectively.
For 2025, Hologic is now projecting non-GAAP EPS of $4.25 to $4.35 compared with the analyst consensus expecting $4.26.
It cut projected revenue for 2025 to $4.05 billion to $4.1 billion from its prior range expecting $4.15 billion to $4.2 billion. The analyst consensus is expecting $4.16 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.